Early Phase 1 N=5 RHD Genotype Matched Red Cells for Anti-D
Sickle Cell Disease · Anti-D Antibodies
Primary: Anti-D Recurrence — 0; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=10 Pupillary Unrest as an Indicator of Central Opioid Effect in Subjects 40-60 Years of Age
Opioid Toxicity · Pupillary Miosis · Respiratory Depression
Primary: Area Under the Time Concentration Curve (AUROC ) — 0.9700 Probability
Phase 1 N=45 Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Relapsed or Refractory Classical Hodgkin Lymphoma
Primary: Part A (Dose Escalation): Number of Participants With Adverse Events (AEs) — 1; 1; 1; 1 Participants
N/A N=39 Clinical Evaluation of a Bulk Fill Resin Composite
Dental Caries · Unsatisfactory or Defective Restoration of Tooth
Primary: FDI 11 - Postoperative Hypersensitivity — 55; 10; 3; 0 Restorations
N/A N=120 HOPE Intervention for COVID-19
COVID-19 Vaccination
Primary: Requests for a COVID-19 Vaccine Resource Sheet — 6; 0 Participants
N/A N=1,822 Caregiver Outcomes of Alzheimer's Disease Screening
Alzheimer Disease
Primary: Short Form Health Survey (SF-36) — 48.4; 47.8; 48.8; 44.7 score on a scale
N/A N=4 Effects of High Intensity Stepping Training on Gait in Patients With Ataxia
Cerebellar Ataxia
Primary: Walking Speed in Meters Per Second as Assessed by the 10 Meter Walk Test(10MWT) — 0.13; 0.60 meters per second
Phase 3 N=484 Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Montgomery-Åsberg Depression Rating Scale — -14.7; -9.8 score on a scale — p=<0.0001
Phase 2 N=32 Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome
Von Hippel-Lindau Syndrome
Primary: Overall Response Rate (Complete Response + Partial Response) — 13 Participants
N/A N=225 Tailored Approaches to Reduce Distress and Improve Self-Management for Veterans With Diabetes
Diabetes · Diabetes Distress · Self-Management
Primary: Aim 1: Differences in Diabetes Distress Scale Score by HbA1c Level (HbA1c < 9 and HbA1c ≥ 9) — 1.907; 2.054 score on a scale
N/A N=354 Brain Health Support Program
Dementia Prevention · Mild Cognitive Impairment · Subjective Cognitive Impairment
Primary: Change in Dementia Literacy From Baseline to Month 12 — 0.191 Score on a scale
Phase 2 N=125 Anti-epileptogenic Effects of Eslicarbazepine Acetate
Post Stroke Epilepsy
Primary: Proportion of Patients Who Experience the First Unprovoked Seizures (US) Within the First 6 Months After Randomisation (Failure Rate) — 2; 7; 3; 0 Participants
Phase 2 N=60 Comparative Usability Evaluation of Sustained Acoustic Medicine (SAM) Devices and Topical Gel for OA Knee Pain
Knee Osteoarthritis
Primary: Change in Pain Units on a Scale (0-10) 0 Being Least, 10 Being Worst Pain From Baseline — -3.56; -3.29; -1.00 units on a scale
Phase 2 N=23 Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213
Chronic Graft-versus-host-disease
Primary: Duration of Response (DOR) — NA; NA months
Phase 4 N=100 The Effect of IV Cangrelor and Oral Ticagrelor Study
Acute Coronary Syndrome (ACS) · High On-treatment Platelet Reactivity (HTPR) · Microvascular Obstruction (MVO)
Primary: Degree of Platelet Inhibition Measured — 248.3; 145.2 Platelet Reactivity Units (PRU)